MedTrace Logo

COMPliance With Avonex® PS in Patients With Relapsing-Remitting MS

NCT00675883 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 1000

Last updated 2012-01-30

No results posted yet for this study

Summary

A phase IV, observational, survey-based study to measure compliance with Avonex® PS therapy in patients with Relapsing-Remitting Multiple Sclerosis, and to compare persistence on therapy 22 months after initial prescription of AVONEX® PS between patients enrolled in the current MS AllianceTM program versus patients enrolled in this program prior to October 2007.

Conditions

  • Multiple Sclerosis, Relapsing-Remitting

Sponsors & Collaborators

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-05-31
Primary Completion
2011-12-31
Completion
2011-12-31

Countries

  • Canada

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00675883 on ClinicalTrials.gov